|Dr. Ragupathy Madiyalakan Ph.D.||Chief Exec. Officer and Director||463.78k||N/A||N/A|
|Mr. Pierre Vermette C.A.||Chief Financial Officer||96.69k||N/A||N/A|
|Mr. Thomas Woo M.Sc.||VP of Product Devel.||109.17k||N/A||N/A|
|Mr. Roger Andrews||Head of Investor Relations & Corp. Communications||N/A||N/A||N/A|
|Mr. Douglas C. Bachman||VP of Corp. Devel.||N/A||N/A||63|
Quest PharmaTech Inc., a biotechnology company, develops and commercializes antibody based immunotherapeutic products for cancer. The company operates in two segments, Biopharmaceutical/Pharmaceutical Products and Consumer/Cosmetic Products. It develops products for treatment of cancer by combining immunotherapeutic antibodies with immunoglobulin G or E, chemotherapy, immune-adjuvants, or photodynamic therapy. The companys lead product candidate is Oregovomab, a monoclonal antibody for the treatment of ovarian cancer, which is in Phase II clinical trial. It also owns the Photodynamic therapy technology for oncology and dermatology applications; markets Bellus Skin serum, an anti-wrinkle skin care product; and develops Mab AR 9.6 against truncated O-glycan on MUC16, for targeted cancer therapy applications. Quest PharmaTech Inc. is headquartered in Edmonton, Canada.
Quest PharmaTech Inc.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.